ePS06.9 Real world introduction of Colobreathe™ in children and adults with cystic fibrosis

Objectives: To evaluate the introduction of ColobreatheTM (Colo) from June to November 2015 in French patients attending 2 paediatric and 2 adult CF centres. Methods: All patients were similarly educated on how to inhale Colo (explanations, video) and received a test dose at the CF centre. Telephone follow-up with a CF caregiver was set up at days 1, 3 and 14 in order to assess tolerance and advise patients. Reasons for treatment interruption during the first month were collected. Results: 123 patients (adults 71%, median age 24 years, mean FEV1 % pred. 64±25) received a test dose of Colo. 67% were previously treated by inhaled colistineand 20% had no inhaled antibiotics. Out of the 112 patients who completed the trial, 27.7% interrupted treatment within one month. The reasons were cough (n =22, 71%), bad taste (n = 3), technical problems (n =4), treatment burden (n =2), urticaria (n = 1), medical decision (n =1) or hemoptysis (n = 1). No difference could be seen between those who had and had not interrupted treatment at one month as to age or FEV1, but patients already treated by inhaled colistinewere less likely to stop treatment. In the 81 patients who completed one month treatment, cough was also frequently reported but its incidence progressively decreased (50% at D1, 36% at D3, and 14% at D30). 13 out of 112 patients (12%) had technical problems, mainly blocking of the device or broken capsule. At one month, treatment burden was scored at 2 (on a 1–10 scale). Conclusion: Education at introduction of Colo resulted in continuation of treatment in 72% of the patients at one month, cough being the major reason for discontinuation of treatment. Long term assessment is needed. ePS06.10 Antibiotic desensitisation: a single centre review of 2015 M.K. Dooney, K.J. Cox, P.J. Barry, A.K. Webb, A.M. Jones, R.J. Bright-Thomas. Manchester Adult Cystic Fibrosis Centre, Manchester, United Kingdom